Today: 11 November 2025
Subscribe
Browse Category

NYSE:UNH News 26 September 2025 - 9 November 2025

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth (UNH) premarket: Dividend set, UBS talk at 8:45 a.m. ET, raised guidance — what to watch on November 10, 2025

Overview (as of Sunday, November 9, 2025)UnitedHealth Group (NYSE: UNH) starts the new week in the spotlight with a live interview at the UBS Global Healthcare Conference before the bell on Monday, alongside a fresh quarterly dividend declaration and a late-October guidance raise. Investors will be parsing any color on 2026 medical-cost trends, Medicare Advantage star ratings and policy tailwinds, ongoing DOJ matters, and integration updates after August’s Amedisys close. Centers for Medicare & Medicaid Services+3SEC+3UnitedHealth Group+3 Top overnight and recent headlines• Dividend: The board authorized a quarterly cash dividend of $2.21 per share, payable Dec. 16, 2025, to shareholders
9 November 2025
 ·  ·  ·  ·  · 
UnitedHealth Stock Rallies After Bold Strategy Overhaul – Is 2026 a Turning Point?

UnitedHealth Stock Rallies After Bold Strategy Overhaul – Is 2026 a Turning Point?

UnitedHealth’s recent earnings and strategic shifts have drawn close market attention. The company’s Q3 2025 results beat expectations, enabling a tighter outlook. Its revenue for Q3 rose 12% to $113.2 billion unitedhealthgroup.com, with adjusted profit of $2.92 per share. That exceeded estimates and allowed management to raise full-year profit guidance. On Oct. 28, UnitedHealth said it now sees 2025 net EPS of at least $16.25 (from $16.00 prior) reuters.com – above the roughly $16.20 analysts had forecast. As portfolio manager Daniel Barasa of Gabelli Funds noted, “the results, the EPS guidance increase, and management commentary were all highly encouraging,” potentially signaling
29 October 2025
 ·  ·  ·  ·  · 
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Stock Soars After Q3 Shock – Is a Bigger Rally Ahead?

UnitedHealth’s third-quarter report released Oct. 28 largely vindicated that turnaround strategy. Revenue climbed 12% year-over-year to $113.2 billion, helped by strong growth in both its insurance (UnitedHealthcare) and health-services (Optum) units businesswire.com. The company delivered adjusted EPS of $2.92, beating the $2.80 Wall Street average marketscreener.com, despite EPS plunging from $7.15 a year ago due to higher costs. On the call, Hemsley noted that results were on track with management’s plan: “We remain focused on strengthening performance and positioning for durable and accelerating growth in 2026 and beyond,” he said marketscreener.com. UnitedHealth also raised its full-year 2025 profit outlook to at least
28 October 2025
 ·  ·  ·  ·  · 
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Market News & Today’s Financial Outlook Stocks are starting today on cautiously optimistic footing. Futures were little changed this morning after a batch of earnings delivered both relief and warnings. Netflix shocked investors with a rare earnings miss, sending its stock down ~6–7% in pre-market trading reuters.com. And chipmaker Texas Instruments sank nearly 9% after issuing a bleak sales forecast, which in turn dragged down other semiconductor names reuters.com. Those disappointments put a slight chill on Nasdaq futures. “We’re at a bit of a point of indecision, where nobody feels particularly strongly about anything,” noted Michael Green of Simplify Asset
22 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
UnitedHealth Stock Rallies to $364 – Will UNH’s 2025 Comeback Last or Fade?

UnitedHealth Stock Rallies to $364 – Will UNH’s 2025 Comeback Last or Fade?

Stock Price Snapshot: October 2025 Rebound UnitedHealth stock has seen volatile swings in 2025, but recent weeks brought a measure of relief. As of Oct. 21, shares trade around $364, up from the lows hit earlier in the year. On Monday (Oct. 20), UNH jumped +2.21% to close at $364.48 investing.com, recovering from a mid-month dip. Over the past week the stock oscillated in the mid-$350s to $360s, essentially flat to slightly higher overall investing.com. Despite this stabilization, UnitedHealth remains deep in the red for 2025. The stock is still down roughly 30–35% year-to-date (depending on the reference point) ts2.tech,
21 October 2025
 ·  ·  ·  ·  · 
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

Current Stock Price and Performance (Oct 8 2025) UnitedHealth Group’s share price has been volatile in 2025. On 8 Oct 2025 the stock closed around $372—IndMoney quoted $372.93 while Investing.com listed $372.64 indmoney.com investing.com. Reuters reported that the last trade was $371.46, up 2.15 % from the previous day reuters.com. The wide 52‑week range ($234.60‑$630.73) highlights the enormous drawdown from April’s peak and underscores the severity of the 2025 sell‑off. The stock’s average daily trading volume is about 5.9 million shares, and its beta of 0.47 indicates less volatility than the S&P 500 reuters.com marketbeat.com. Year‑to‑date performance remains negative (‑28 % to ‑37 % depending on the reference period),
8 October 2025
 ·  ·  ·  ·  · 
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Key facts (25–26 Sept 2025) What happened—and why it mattered UnitedHealthcare coverage win. On Sept. 25, Plus Therapeutics announced that UnitedHealthcare Insurance Company (UNH) granted national coverage for its CNSide® CSF Tumor Cell Enumeration LDT for metastatic CNS cancer, effective Sept. 15. The deal potentially opens access to more than 51 million members nationwide and positions CNSide as a covered testing service for specialists treating leptomeningeal metastases (LM)—a devastating complication of advanced cancers. GlobeNewswire What the test does. The CNSide platform supports rapid diagnosis, treatment monitoring and guidance in LM. Plus Therapeutics reports >11,000 tests performed across 120+ institutions since
26 September 2025
 ·  ·  ·  ·  ·  · 
Go toTop